Q-linea provides a business update before closing and reports its Q2 result later in July.
Sprint Bioscience has entered a research collaboration with the Experimental Drug Development Centre...
Forward-looking metrics a bit on the soft side Competitor and peer Accenture reported its Q3'25 repo...
Biovica continues to increase 12m rolling IVD test sales in Q4 of SEK 0.
Alisa Bank issued a profit warning, with continued weaker demand driving lower volumes.
Redeye re-initiates coverage of marketing technology company Eniro Group, perceiving the company to ...
Redeye provides a comment on Verve’s announcement of a directed share issue which strengthens the co...
Redeye comments on the topline data from the phase II study POSITANO, which investigates the effect ...
Key milestone for readiness Prolight has reported positive interim results from the ongoing patient ...
Redeye comments on Scibase entering a collaboration and license agreement with Castle Biosciences an...
Q2 report due 18 July Q2e net sales SEK 555m, EBITA SEK 79m We leave our FVR unchanged at SEK 44-59 ...
Redeye comments on Kontigo Care’s new strategic partnership with Feelgood, Sweden’s largest occupati...
We initiate coverage of Nokian Panimo with a target price of EUR 2.
Redeye comments on Alzinova’s recent announcements of a strategic collaboration with Worldwide Clini...
Redeye re-initiates coverage of Isofol Medical, a Swedish oncology biotech company targeting the mul...
Q2 report due 17 July 2025 Q2e net sales of SEK 189m and EBITA of SEK 24m We reiterate our fair valu...
Redeye comments on Alzecure announcing a rights issue of up to SEK58.
Redeye reduces its forecasts and Base Case in Hexatronic slightly on the back of FX and the revised ...
Moberg Pharma successfully launched Teclara in Sweden last year, and the early initial feedback from...
Redeye comments on Kancera reporting positive top-line results in its phase Ib/IIa KANDOVA study wit...
